NEW (mouse) STUDY:
-How sertraline (Zoloft) disrupts testosterone biosynthesis.
Sertraline disassembles the mitochondrial transduceosome.
This mechanism may help explain why Zoloft is associated with sexual dysfunction.
(Fetal testicles also produce testosterone—which is essential for normal male fetal sexual development.) (1/2) sciencedirect.com/science/ar…
Biological psychiatry, a total failure. Thomas Insel, the director of the US National Institute of Mental Health from 2002 to 2015, said in an interview in 2017: “I spent 13 years at NIMH really pushing on the neuroscience and genetics of mental disorders, and when I look back on that I realize that while I think I succeeded at getting lots of really cool papers published by cool scientists at fairly large costs - I think $20 billion - I don’t think we moved the needle in reducing suicide, reducing hospitalizations, improving recovery for the tens of millions of people who have mental illness. I hold myself accountable for that.” bit.ly/3Vs7fGH
Psychiatrists often say: "80% of psych meds are written by PCPs."
The data: PCPs wrote about half (51%) of psychotropic prescriptions in 2022, down from 64% in 2013. It may have been 80% at some point, or in other settings, this is Medicare Part D.
I am not a fan of blaming primary care for overprescribing. In my experience, PCPs (my grandfather was one) tend to follow guidelines and algorithms. In psychiatry, those are generally written by psychiatrists, or based on our work.
If PCPs are doing it wrong, or shouldn't prescribe psychotropics at all, we should say so much more clearly, and explain why.
Ref: Hooker et al., Medical Care 2026
I've responded briefly to Jack's blog here: mhorowitz.substack.com/p/une…
The two major problems with Jack Goulder’s blog (and the paper on which it is based) is, one, that Jack is working from the unquestioning (and largely unexamined) assumption that antidepressants work and anyone who suggests otherwise must have mischievous motivation. And two, he has misrepresented what we have said about our umbrella review.
Jack said to me tellingly in an email:
“I should be clear that my academic background is in history and social science, not epidemiology or pharmacology. I’m not sure I’m qualified to give a detailed analysis of the subtleties of this quite vast literature!”
So without engaging with the debate about efficacy in any meaningful way he has embarked on what sounds like a year-long project on the premise that ‘the drugs work because senior people in my field agree they do’ and that he saw a young woman (with a different condition to the literature he is commenting on) improve with antidepressants ‘after a few months, and with the help of therapy too.’
This is not how science works. I sent him a very clear explanation of the issues with antidepressant efficacy written by a Cochrane group in Denmark – who I’m sure have never read Szasz! – published in the BMJ Open but he seems not to have read this: bmjopen.bmj.com/content/9/6/…
To just briefly re-state the issues with the Cipriani review on antidepressants (which provides the basis of Jack and other’s unshakeable belief in the efficacy of these drugs): presenting response rates inflates the small absolute differences between antidepressant and placebo.1 This difference is 2 points on a 52 point depression scale.2 This lies below any analysis of what constitutes a clinically important difference (rather than just a statistically significant difference).3,4 See figure above to illustrate some of these elements. These studies only examine effects at 8 weeks, whilst people take these drugs for years.5 Even the small effects at 8 weeks are likely to wear off due to tolerance – the corollary of any drug that causes withdrawal.6
There are also unblinding effects – people who know they are on the drugs have raised expectations which improve mood and these expectations inflate the apparent effects of antidepressants in placebo-controlled trials.7 For example, in an analysis of the TADS study treatment guess had a substantial effect on outcome, while actual treatment group (antidepressant or placebo) did not.7 The Stone et al meta-analysis did not refute the role of unblinding as Jack suggests, it merely notes that the trials it included did not test the integrity of the double blind design (Stone writes “We cannot fully exclude the possibility that the effects of the drugs are accounted for by functional unblinding”). 8
There is also massive publication bias.9 The studies which find 15% of people benefit at an 8 week time point suffer from all the same limitations as above.8 And if there is a small pharmacological effect in the short term from this class of medication it leaves the question of the utility – or the ethics – of giving people drugs that numb their emotions when they are distressed,10 especially with the risk that for a portion of them this numbing does not wear off when the drugs are stopped.11,12 Jack’s piece ignores almost all of these issues.
A central part of this argument is that Joanna and I put out a press release arguing that our paper had demonstrated antidepressants are ineffective. Notably he does not quote the lines from the press release in his blog or the paper – remarkable when this is a key part of his argument.
Of course the reason he does not quote this is because his assertion is false. We don’t anywhere say in our draft press release that we have demonstrated in our umbrella review of the role of serotonin in depression that we have demonstrated that antidepressants are not effective. The closest we come is when we say: “Therefore, this research calls into question reasons for the use of antidepressants.” The research does indeed undermine a common reason for the prescription of antidepressants.
I think what is most unsettling about this piece is that Jack has inverted the work of Naomi Oreskes. Her work and her book Merchants of Doubt sets out the playbook taken by large industries to undermine critics of their hegemony. When big tobacco was being criticised for causing lung cancer by researchers, it funded researchers who sewed doubt in this hypothesis by pointing to asbestos, stress, etc, anything other than tobacco which might cause lung cancer.
The same playbook was used by fossil fuel companies: as climate scientists started pointing the finger at this industry for driving climate change, scientists associated with industry put out arguments sewing doubt: temperatures natural vary, humans couldn’t be doing it, etc.
This is the identical playbook adopted by the pharmaceutical industry and its supporters when it comes to obscuring the harm of their products. Antidepressant withdrawal isn’t caused by stopping antidepressants, they say, it is caused by patient’s expectations of worsening (nocebo effects), their mental health condition returning, other diseases that co-incidentally occur at the same point (functional neurological disorder) and short-term withdrawal studies show that there is no real issue, etc.13,14
There is an absurdity to painting academics, many of whom are paid by one of the largest industries in the world as representing unimpeachably pure science and Joanna and a bunch of her academic colleagues (including me) as the ‘merchants of doubt’. Of course some of the scientists who defend the efficacy or minimise the harms of antidepressants are not paid by industry, but other interests, such as professional status, are also at play.
I would strongly encourage Jack and anyone reading his essay to go and read criticisms of antidepressant efficacy before jumping to conclusions that anyone putting forward a criticism of the current consensus must be mischieviously motivated.
The current (and poorly examined) consensus on the relative safety and effectiveness of antidepressants in the long-term has led to an avalanche of harm that can be seen spilling out onto social media, newspaper articles, government inquiries, parliamentary groups and, increasingly, concrete NHS projects and directives. Rather than expending further energy trying to shoot (and silence) some of the messengers it would be better for patients if psychiatrists examined the reality of what is occurring to patients and stopped deriving false reassurance from short term studies centrally concerned with commercial objectives.
References available at: mhorowitz.substack.com/p/une…
Merchants of Psychiatric Doubt
Why a small group of researchers diverged from their peers on the science of antidepressants
A guest post by @jack_goulderpsychiatrymargins.com/p/merc…
Another large study finds ADHD meds don't improve school performance, at least for kids on the margin of treatment.
I remain unsure what ADHD is. I was taught it was a delay in maturation that resolved. Later, a lifelong disorder of attention. More recently, a problem of alertness and reward pathways more than attention.
Either way, parents and teachers often push medication hoping to improve grades.
This study looked at all children aged 5 to 15 in Norway. It used differences in how clinics prescribe as a natural experiment. Using this analysis academic benefits of medication disappeared.
"For children and adolescents on the margin of pharmacological treatment for ADHD, we found no causal effect of pharmacological treatment on any of our measures of academic performance."
DOI: 10.1192/bjp.2026.10754
Picture: Figure 2(b) showing that GPA doesn’t significantly increase with meds using the instrumental variable analysis.
81% of ECT patients in the largest survey to date said their memory problems lasted more than 3 years.
That survey looked at 1,141 patients and their families. People said they couldn't remember their wedding, their kids' birthdays, even their whole nursing career.
Many psychiatry websites still say memory problems usually clear within 2 months.
What I see is people on a soup of 5 or 6 drugs, getting worse from side effects, then told they have "treatment resistant depression" and sent for ECT.
Before that, someone should look at the drugs and remove them gradually. Never stop suddenly. Do it slowly, with a prescriber.
Comment TAPER and I'll send you my free safe tapering guide.
A new study funded by the Wellcome Trust will take people off antidepressants over 4 weeks and will measure serotonin levels (using a brain scan following tryptophan depletion) to predict who will relapse. There are 9 measures of relapse or mood symptoms. There are no measures of withdrawal.
pradam.org
DSM-6 is a grift/mistake whose only real purpose is publishing profits for Am Psychiatric Assoc.
Changing its name from 'Diagnostic & Statistical Manual' to 'Diagnostic & Scientific Manual' is putting lipstick on a pig.
Giant leaps in neuroscience during past 50 yrs have had absolutely no impact on diagnosis.
At a time when many established scientific practices are being questioned, including vaccines and other longstanding evidence-based public health interventions, how does changing the name of the DSM help? 🔗👇
I think people are not aware of how much mis-information is propagated about this class of medications.
I remember being taught to say this to patients: that the increase in suicidality is caused by an increase in energy before an improvement in mood.
What studies show is simply an increase in suicidality when people are given these medications compared to placebo.
How many people have been talked into taking these medications because of the repetition of these talking points by prescribers?
Who Are the Real Purveyors of Medical Misinformation?
One of the most troubling things about psychiatry is how speculative explanations for drug harms become established facts through sheer repetition.
Take the claim that SSRIs can increase suicidality because they restore a depressed person’s energy before improving their mood, supposedly giving them the motivation to act on existing suicidal thoughts.
This is routinely presented as though it’s an established scientific explanation.
It isn’t. It’s a longstanding hypothesis for which convincing empirical evidence is lacking.
A 2009 review in Psychiatric Services examined this very theory and found no consistent evidence supporting it.
Yet rather than acknowledging that these drugs can themselves produce adverse psychological reactions, including agitation and akathisia, we’re offered a reassuring story about patients getting better.
It’s a striking example of how a superficially plausible sounding hypothesis can become received wisdom when it conveniently distracts from uncomfortable truths about drug harm.
Just because something is repeated as fact by someone in a white coat doesn’t make it any more true than any other forms of misinformation we hear online.
And when we see it we should call it out.
Psychiatry discovers that "night owls" with poor sleep habits have a type of "atypical depression" that responds better to improved sleep habits than to antidepressants.
No matter the situation, psychiatry cannot admit that it's wrong.
Gift article. nytimes.com/2026/10/23/well/…
Mental health professionals being servile to psychiatry out of fear, ignorance or a quiet hope to make friends in higher places, is a frustrating thing to so widely observe.
"A final sample of 19,155 long-term antidepressant users were compared with 20,648 propensity score matched nonusers. After adjusting for covariates, long-term antidepressant use was significantly associated with dementia (odds ratio [OR] 1.92, 95% [CI] 1.72–2.15, p < 0.001)."